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Lyme borreliosis (LB) is the most common tick-borne disease caused by the spirochete
Borrelia burgdorferi in North America and Borrelia afzelii or Borrelia garinii in Europe
and Asia, respectively. The infection affects multiple organ systems, including the skin,
joints, and the nervous system. Lyme neuroborreliosis (LNB) is the most dangerous
manifestation of Lyme disease, occurring in 10–15% of infected individuals. During the
course of the infection, bacteria migrate through the host tissues altering the coagulation
and fibrinolysis pathways and the immune response, reaching the central nervous
system (CNS) within 2 weeks after the bite of an infected tick. The early treatment
with oral antimicrobials is effective in the majority of patients with LNB. Nevertheless,
persistent forms of LNB are relatively common, despite targeted antibiotic therapy. It has
been observed that the antibiotic resistance and the reoccurrence of Lyme disease are
associated with biofilm-like aggregates in B. burgdorferi, B. afzelii, and B. garinii, both
in vitro and in vivo, allowing Borrelia spp. to resist to adverse environmental conditions.
Indeed, the increased tolerance to antibiotics described in the persisting forms of Borrelia
spp., is strongly reminiscent of biofilm growing bacteria, suggesting a possible role of
biofilm aggregates in the development of the different manifestations of Lyme disease
including LNB.
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INTRODUCTION
Lyme borreliosis (LB) is the most prevalent vector-borne disease (1) caused by the spirochete
Borrelia burgdorferi. This Gram-negative bacterium is an obligate pathogen, transmitted to
different hosts by ticks in the genus Ixodes. LB is frequently reported in North America, Europe, in
different parts of Asia, including Mongolia and China as well as in Australia and in Africa (2–4).
LB affects multiple organ systems, including the skin, eyes, joints, muscles, cardiac, and nervous
system, presenting, at different stages, with a variety of clinical manifestations (5). Incubation varies
from 3 to 32 days, after which a characteristic skin rash, known as erythema migrans, appears in
association with fever, headache, malaise, and myalgias (stage 1) (6). After several weeks to months,
in 8–15% of patients can be reported the presence of neurologic and cardiac abnormalities (stage 2).
Within few weeks, in untreated patients or in case of delayed antibiotic treatment, the infection can
disseminate leading to systemic inflammation (7, 8). In the last phase of LB (stage 3), patients may
experience chronic monoarticular or oligoarticular arthritis, involving large joints, particularly the
knee (9–11).
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The most severe manifestations of LB, is Lyme
neuroborreliosis (LNB), reported in 10–15% of individuals
with localized erythema migrans (12, 13). The activation of the
inflammatory response in LNB contributes to the pathogenesis of
a broad spectrum of neurologic disorders. Different geographical
distribution of B. burgdorferi species correlates with specific
manifestation of LNB, which is more frequent in Europe than
in the North America (6). The most common symptoms
of LNB in Europe are painful meningoradiculitis known as
Bannwarth syndrome and facial nerve palsy (14). Symptoms
involving the central nervous system (CNS) are less common
and their exact incidence is not known. B. burgdorferi infection
of the CNS cause mainly encephalitis, segmental myelitis,
cranial neuritis, radiculoneuritis, vasculitis, and intracranial
hypertension (13, 15, 16). The clinical manifestation of the
LNB may include ataxia, paraparesis, sphincter dysfunction,
Parkinson-like symptoms, confusion and cognitive impairment
(17, 18). Ischemic stroke is the most frequent cerebrovascular
manifestation of LNB presenting in 76% of cases, followed by
transient ischemic attack (11%) (19).
LNB is, inmany cases, responsive to appropriate antimicrobial
therapy and the clinical improvement sustained by the antibiotic
treatment provide further evidence for the direct contribution
of B. burgdorferi in disease pathogenesis. However, the chronic
persistence, the frequent reoccurrence of LNB and the ability of
B. burgdorferi to tolerate multiple cycles of antibiotic treatment
is strongly suggestive for the formation of biofilm or biofilm-
like protective structure (20–23). Indeed, different studies have
shown that B. burgdorferi can switch from amotile to a stationary
status, in which the cells are embedded within a biofilm matrix
(22). B. burgdorferi biofilms have been observed both in vitro and
in human infected skin tissues (22, 23). These structures express
differentmucopolysaccharides, particularly alginate, extracellular
DNA and calcium, which are all typical markers of biofilm (22).
The presence of biofilm may explain the low rate of Borrelia
detection in the blood of infected patients as well as the ability
of the spirochetes to evade the host immune system and resist the
antibiotic therapy (21, 24–27).
This review investigates the differences in the epidemiology
and clinical manifestations of LNB with particular emphasis on
the pathogenetic role of B. burgdorferi biofilm in tissue adhesion,
colonization and survival.
MATERIALS AND METHODS
The present review focuses on a systematic review of the literature
to identify all published articles of LNB using online databases
(PubMed, Web of Science, and Google Scholar). The reference
list was updated in September 2018. There were no language
restrictions; The search terms were “Borrelia,” “B. burgdorferi,”
“Borrelia biofilm,” “Lyme disease,” “neuroborreliosis,” “LNB,”
“borreliosis.” We reviewed titles, abstracts, case reports, and
full articles to assess their relationship with the research
criteria. References reported in each article were also reviewed
to identify additional study not found by initial search
terms.
Epidemiology of Borrelia burgdorferi
Infection
LB is increasing worldwide with ∼300,000 new cases annually in
the United States and 85,000 cases in Europe each year (28–30).
Incidence of human LB in endemic areas of the United States
ranges from 10 to 100 per 100,000 population with a peak of
134 per 100,000, reported in Connecticut in 2002 (4, 31, 32). The
number of documented LB cases and the geographic distribution
has expanded during the last two decades, from the Northeastern
and North Central United States (4). LB is widespread also in
Europe and the incidence for LB ranges from 20 to 80 per 100,000
in the Czech Republic, Germany, Latvia, theNetherlands, Poland,
Switzerland, and Sweden, peaking to more than 100 per 100,000
in Austria, Estonia, Lithuania, and Slovenia (4, 29, 33, 34).
Incidence of LB decreases southward, in Spain, France, Italy, and
Greece with approximately 1 case per 100,000 (4, 29).
B. burgdorferi sensu stricto, B. garinii, and B. afzelii, are
primarily responsible for human LB in different geographical
regions presenting specific symptoms (34–38).
The genomes of Borrelia species consist of a set of circular and
linear plasmids and a linear chromosome of∼900 kb ending with
DNA sequences regulated by breakage and reunion reactions
(39, 40). Different isolates show a variable number of plasmids
depending on the species and affected by frequent reorganization
(41–47). B. burgdorferi B31 strain harbors 10 circulars and 12
linear plasmids while B. afzelii B023 and B. garinii CIP 103362
have 6 linear and 2 circular plasmids and 4 linear and 1 circular
plasmids in Fraser et al. (41), Casjens et al. (42), and Bontemps-
Gallo et al. (47).
Most of the essential genes involved in metabolism or
regulation are located in the linear chromosome while only
a subset of genes encoding proteins required for growth and
specific virulence factors are located on plasmids (41, 48–50).
B. burgdorferi sensu stricto is the predominant causative
agent of LB, Lyme arthritis, and also LNB in the United States
(51). Nevertheless, consistent differences in the ability to
induce LB exist between B. burgdorferi sensu stricto subtypes
suggesting that, neurotropism is an ability present only in a
restricted subtype of Borrelia (52, 53). Different genotypes
of B. burgdorferi sensu stricto diverge ecologically and
epidemiologically, suggesting that genotype classification is
relevant to understanding the basic biology of the spirochete
(54–56). Studies conducted in endemic areas of the United States
revealed that patients with disseminated infection were more
likely infected by the RST1 strains of B. burgdorferi than with
RST3 strains (57, 58). Moreover, dissemination of B. burgdorferi
to blood or cerebrospinal fluid (CSF) was mostly related to ospC
genotypes A, B, I, or K (58–62).
The distribution and relative frequency of infection by
the different genospecies of Borrelia sensu latu vary across
European regions. B. burgdorferi sensu lato comprises 20
different genospecies and this diversity correlates with the large
variability in the clinical manifestations observed in LB (4,
13, 63). In the northern and eastern Europe B. afzelii is the
most prevalent species, whereas in Western European countries
B. garinii is the most common pathogen (4, 29). B. afzelii,
B. garini, and the recently identified species B. bavariensis
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are major cause of LB and LNB in Europe (52, 64–68). The
heterogeneity among B. burgdorferi sensu lato genospecies is
linked to different geographical areas, which, in turn, correlates
with the different clinical expression of human LB (69). For
instance, B. afzelii induces prevalently skin infections, whereas
B. garinii is in most cases neurotropic (5, 69). Other species,
such as B. lusitaniae or B. valaisiana, have only occasionally
been associated with human disease (70–72). In endemic areas of
Europe was proposed that the variety of symptoms observed in
children and adults with LNB correlated with the B. burgdorferi
sensu lato genotype (73–75). Individuals with erythema migrans
caused by B. afzelii and B. garinii showed distinct epidemiological
and clinical characteristics. Indeed, erythema migrans caused
by B. garinii were located prevalently on the trunk and less
often on extremities, had shorter incubation and faster evolution,
leading to frequent systemic symptoms, abnormal liver function
test results than individuals with erythema migrans caused by
B. afzelii (76, 77).
The genetic diversity observed in B. burgdorferi, at both inter-
and intra-species level, is probably the reason for the multiple
epidemiological and clinical presentation of these bacteria in
humans (62, 78–80). Amajor role inmaintaining the intraspecific
genetic diversity of B. burgdorferi is the adaptation to multiple
vertebrate hosts, which act as ecological niches for different
genotypes (81, 82). Consequently, variations in the vertebrate
host fitness may result in changes in the abundance of the more
pathogenic species (83–85).
Host Invasion Strategies of Borrelia
burgdorferi
Colonization, dissemination and invasion of the tick vector
and mammalian host by B. burgdorferi requires a complex
temporal and spatial regulation of borrelial genes to adapt to
environmental challenges. Transition of B. burgdorferi from
the tick midgut to the hemolymph during a blood meal is an
important step for bacterial diffusion through the salivary glands
to a mammalian host (86). Borrelia possesses a sophisticated
mechanism of gene regulation based on the two-component
pathways HK1/Rrp1 and Rrp2-RpoN-RpoS, which regulate
metabolism, antigenic variation, chemotaxis, and adhesion in a
tissue- and temporal-specific manner in both the tick vector and
mammalian host (48, 87). During the blood uptake B. burgdorferi
expresses the outer surface proteins (Osp) A and B. These
proteins mediate the adherence to the tick’s gut by the binding
to the tick receptor of OspA (TROSPA), thus facilitating the
subsequent transmission into the mammalian host (88–90).
Infection of the mammalian host requires the migration of
the spirochetes from the midgut to the salivary glands of the
tick. After the blood uptake into the midgut of the tick, the
production of OspA and OspB decrease while ospC is expressed
in conjunction with many other genes controlled by the RpoN,
RpoS, and Rrp2 system (90–96).
OspC is required to establish the early phase of B. burgdorferi
infection in mammalian host and to promote evasion from the
innate immune defenses (96–98). Different studies revealed that
the OspC mutant strains are unable to establish infection in
mice, suggesting a protective role of this protein against host
innate defenses (96, 99–104). Nevertheless, to escape from the
host immune system, the expression of ospC decreases within
2–3 weeks after infection in response to anti-OspC antibodies in
mice (105, 106). In addition to OspC, B. burgdorferi hides other
important immunogenic surface proteins (107). In particular,
OspA, which stimulates neutrophils and a strong inflammatory
response mediated by interleukin (IL)-1β, tumor necrosis factor
(TNF)-α, and IL-6, is highly expressed in the tick gut but it
is rapidly downregulated in the host (108–112). OspA-positive
strains of B. burgdorferi penetrate the host, but are unable to
establish an infection (113). Similarly, Borrelia strains isolated
frommice 4 days after infection, were found to be OspA negative
suggesting that this protein is not expressed in the early phase of
the host infection (114, 115).
The expression of different proteins, including OspC, ErpP,
ErpA, ErpC, and enolase is required to readily immobilize
host plasminogen on spirochetal surface, facilitating efficient
dissemination (116–118). Plasminogen is a glycoprotein
produced by the liver and abundant in the plasma and in
certain tissues (119). Conversion of plasminogen to active
plasmin is promoted by proteolytic activation induced by either
tissue-type plasminogen activator (tPA) and/or urokinase-type
plasminogen activator urokinase (uPA). Plasmin is responsible
for intravascular fibrinolysis and contributes to numerous
physiological and pathological processes, including tissue
remodeling, cell migration, thrombolysis, wound healing, and
cancer progression (120, 121). Invasive forms of B. burgdorferi
are known to expresses multiple plasminogen-binding surface
proteins that likely assist pathogen dissemination through host
tissues (120, 122). Enolase is an integral enzyme of the glycolysis
and gluconeogenesis pathways, and a multifunctional protein
found in both prokaryote and eukaryotes (123). In eukaryotic
cells, surface enolase acts as a plasminogen receptor in certain
tumor cells (123, 124). Similarly, this enzyme is also localized
on the cell surface of different microorganisms including
B. burgdorferi (118, 125–127). The surface-localized enolase
acts as a plasminogen receptor contributing to spirochetal
survival in feeding ticks (118). Although dispensable for
infection, plasminogen is required for dissemination in ticks,
and its absence is associated with a decreased spirochetemia
in plasminogen-deficient mice (128). Surface-associated
plasmin on B. burgdorferi degrade fibronectin, which is an
important component of the ECM, laminin and vitronectin
(129, 130). B. burgdorferi also induces the release of host matrix
metalloproteases 9 (MMP-9) and MMP-1, and plasmin-coated
B. burgdorferi activates pro-MMP-9, leading to degradation of
basement membranes (131).
B. burgdorferi exhibits a specific affinity for the CNS as
demonstrated by the presence of spirochetes in the human CSF
within 14–18 days after the tick bite (18, 132, 133). From the
initial site of entry in the skin the spirochetes can reach the CNS
either through the bloodstream or, alternatively, by the peripheral
nerves (114).
Hematogenous dissemination from the tick bite on the skin
to the CNS is a key pathogenetic event in LNB (114). However,
it has been proposed that, at least for B. garinii which is mostly
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responsible for LNB in Europe, spirochetes can pass along the
peripheral nerves (114). To penetrate the brain, spirochetes
must first cross the blood-brain barrier reaching the brain
microvascular endothelium and astrocytes (134). This barrier is
composed by the brain microvascular endothelial cells (BMEC),
astrocytes, basement membrane, pericytes, and neurons. The
BMEC are firmly held together by tight junctions, presenting
with a reduced transcytotic vesicles and an absence of fenestrae.
All of these elements contribute to reduce the transport of
solutes defending the brain from most pathogens or toxic agents
(135, 136). Invasion of the blood-brain barrier by B. burgdorferi
is still a matter of debate. Some studies suggest that Borrelia
uses a paracellular route of translocation (134, 137), although
other evidences suggest a possible transcellular passage of the
spirochetes (138). Neurotropic B. burgdorferi strains showed the
activation of the host plasminogen system, MMPs, and calcium
signaling pathway to facilitate an efficient translocation through
the blood-brain barrier (120, 134, 139). Compelling evidence
suggest that spirochetes can adhere to murine neural and glial cell
lines, primary neural cells, and primary rat brain cultures (140).
In addition, in vitro studies show that B. burgdorferi can promote
an intracellular invasion of human fibroblast, umbilical vein
endothelial, synovial, neuronal, and glial cells without affecting
the cell viability. This suggests that spirochetal cellular invasion
may provide a mechanism for immune evasion and disease
pathogenesis (140–142).
Lyme Neuroborreliosis
A common clinical and pathological manifestations of LNB in
Europe is painful lymphocytic meningoradiculitis also known
as Bannwarth syndrome, frequently accompanied by CSF signs
of inflammation (13, 14, 143). The early manifestation of LNB
generally appears within 2–18 weeks after infection (13, 143).
The clinical description of painful meningoradiculitis was first
reported in 1922, but the etiology remained unknown till the
isolation of spirochetes by Burgdorfer in 1982 and the isolation
in 1984 of spirochetes from the CSF of a patient with Bannwarth
syndrome (144–146).
In addition to Bannwarth syndrome, other important
neurological symptoms of the early stages of LNB
include meningitis, meningeal perivascular, and vasculitic
lymphoplasmocytic infiltrates, neuritis, and in rare acute LNB
cases encephalitis and myelitis (143, 147). CNS vasculitis are
rare in LNB, affecting mainly the large/medium-sized vessels and
are associated with ischemia and stroke (19, 148). However, in
European patients with LNB the mortality rate is comparable to
that of the general population. Nevertheless, LNB is associated
with increased risk of hematological and non-melanoma skin
cancers (149).
Treatment with conventional intravenous antibiotic therapy,
leads, in most cases, to a gradual improvement of the symptoms
after several weeks or months, accompanied frequently by
a normalization of CSF findings (150, 151). However, <2%
of patients treated for LNB experience late neurological
manifestations that persist months or years after B. burgdorferi
infection (14, 143). The clinical symptoms of late LNB
include several neurological and psychiatric symptoms such
as meningoradiculitis, encephalomyelitis, chronic meningitis,
and cerebral vasculitis (152–154). The presence of depressive
states was described in 26–66% of patients with late LNB
together with psychosis, schizophrenia, hallucinations, paranoia,
anorexia nervosa, obsessive-compulsive disorder, and dementia
(155–163). A frequent manifestation appearing in the late stage
of LNB is the chronic vascular damage, clinically characterized by
recurrent stroke or transient ischemic attacks (153, 154). Other
distinctive findings in patients with late LNB are inflammatory
CSF changes (CSF pleocytosis and elevated total protein content)
and the presence of specific B. burgdorferi intrathecal antibody
(150, 151).
The clinical outcome of antibiotic treatment of either early
or late manifestations of LNB may include progression to a
chronic form characterized by nonspecific and persistent fatigue,
arthralgia, myalgia, musculoskeletal, and cognitive symptoms.
This condition, frequently defined as posttreatment Lyme disease
syndrome (PTLDS), can be intermittent or persistent, lasting
for at least six or more months after completion of antibiotic
treatment (143, 164).
Specific diagnostic criteria for PTLDS proposed by the
Infectious Disease Society of America relies on the objective
proof of previous LB, the presence of subjective symptoms
that compromise function in daily life, and the absence of
clinical evidences for another underlying illness (7). However,
those criteria have rarely used in clinical studies, contributing
to confusion and controversy about the clinical significance of
PTLDS syndrome (7). The frequency of PTLDS among patients
with LB varies largely, ranging from 0 to 50%, depending
upon differences in study design and enrollment criteria (165,
166). A long-term follow-up study of patients with early
presentation of erythema migrans and treated with antibiotics at
the time of diagnosis showed an excellent rate of remission, with
only 4% of patients remaining symptomatic during follow-up
evaluation (167). Conversely, other trials reported rates of PTLDS
ranging from approximatively 10–20% (168). Nevertheless, in
the community medical practice, where prompt LB diagnosis
and treatment are not common, PTLDS rates may reach 50%
(169, 170). Notably, xenodiagnoses demonstrated the presence of
B. burgdorferi DNA in a patient with PTLDS, despite repeated
cycles of antibiotic treatments (171). B. burgdorferi DNA was
detected in mice after prolonged (up to 12 months) treatment
with antibiotics despite the persistence of non-cultivable bacteria.
Moreover, the study revealed B. burgdorferi DNA and the
presence of RNA transcripts of multiple spirochetal genes in
host tissues (172). These findings suggest that B. burgdorferi
persist within the host indicating that the immune system and
antimicrobial treatment may not be effective at eradicating
B. burgdorferi. This may contribute to antibiotic-refractory
arthritis, as observed in a murine model in which spirochetal
antigens, but not infectious spirochetes, were recovered near
cartilage for extended periods after LB therapy (173).
According to the guidelines of the European Federation
of Neurological Sciences and the Infectious Diseases Society
of America, treatment with beta-lactams antibiotics, like
ceftriaxone, penicillin, or cefotaxime, or oral doxycycline
for 14–21 days is recommended for the treatment of LNB
Frontiers in Neurology | www.frontiersin.org 4 December 2018 | Volume 9 | Article 1048
Di Domenico et al. Biofilm in Lyme Neuroborreliosis
(7, 25, 174). Intravenous administration of ceftriaxone is often
recommended for the treatment of Lyme meningitis. Oral
treatment with doxycycline demonstrated to be as effective as
ceftriaxone for Lyme meningitis in adults in Europe, although
not recommended as first-line therapy in the United States
(175). Nevertheless, four NIH-sponsored trials aimed at assessing
the administration of antibiotic treatment in patients with
persistent unexplained symptoms despite previous antimicrobial
treatment of LB indicated that the new treatment cycle
provides little if any clinical benefit (176). A randomized,
double-blinded, placebo-controlled trial conducted in Europe,
in patients with persistent symptoms attributed to Lyme
disease showed that longer-term antibiotic treatment did
not have a better outcome as compared with shorter-term
treatment (177).
Biofilm Production and Antimicrobial
Tolerance in Borrelia burgdorferi
B. burgdorferi can switch from motile cellular forms into several
defensive morphological forms such as round bodies, stationary
phase, persister cells, and biofilm (23, 24, 178–182). Transition
between differentmorphologies represents an adaptation strategy
to survive in unfavorable environmental conditions, including
pH variations, nutrient starvation, host immune system attacks,
or the presence of antimicrobial agents (21, 23, 24, 172, 179,
181).
Notably, within the biofilm, bacteria are physically joined
together producing a matrix, characterized by the presence
of an extracellular polymeric substance (EPS) composed by
polysaccharides, proteins, and extracellular DNA (183). Bacterial
biofilms are intrinsically more resistant to environmental
agents and antimicrobials than the corresponding planktonic
counterpart and this can lead to chronic and recurrent infections
(184–186). In vitro and in vivo studies revealed that both
B. burgdorferi sensu stricto and sensu lato (B. afzelii and
B. garinii) aggregates, but not free-floating spirochetes, present
typical markers found in the EPS of other pathogenic bacteria
such as sulfated mucins, non-sulfated mucins (mainly alginate),
extracellular DNA and calcium (22, 23, 187). B. burgdorferi
biofilm is also characterized by the presence of a distinctive
architecture with channel-like elements that in mature biofilm
are required for oxygen and nutrient diffusion and waste
removal (22, 23, 187). Biofilm formation by B. burgdorferi
follows the same evolution described for other bacteria. Initially,
individual spirochetes adhere to biotic or abiotic surfaces forming
microcolonies, coated by the EPS. From this point, Borrelia
aggregates expand undergoing changes in the growth rate, gene
expression and structural rearrangements in the EPS components
(22, 23). The rapid rearrangements occurring within the biofilm
matrix, culminate in a complex three-dimensional structure
with common traits observed among Borrelia genera (Figure 1)
(23, 189). The existence of biofilm-like structures was further
found in human skin biopsies obtained from patients with
borrelial lymphocytoma, a common manifestation of LB in
Europe, revealing the presence of Borrelia-positive aggregates
characterized by mucopolysaccharides, especially alginate (22).
Other reports demonstrated that Borrelia DNA is deposited
in the Alzheimer brain showing structural similarities between
spirochetal aggregates and the profiles of amyloid plaques in
patients with Alzheimer disease (188, 190). Nevertheless, the
specific contribution of biofilm to borrelial persistent infections
remain unclear. Besides, additional in vivo studies showed the
presence of Borrelia aggregates in the midguts of naturally-
infected nymphs during their blood meal (191). These results
strongly suggest that biofilm may contribute to the spirochetal
successful transmission to the mammalian host and to the
ensuing disease manifestations (191).
Biofilm production in Borrelia requires the modulation of a
complex array of signaling processes which allows spirochetes
to communicate with the surrounding environment. The
RpoN–RpoS alternative sigma factor and the LuxS quorum-
sensing pathways, which are involved in several cellular functions
in response to environmental stresses (pH and temperature
variations, high osmolarity, oxidative stress, high cell density,
nutrient starvation, host infection), participate in biofilm
production in B. burgdorferi (22, 192). The RpoN–RpoS pathway,
also known as the σ54-σS cascade, regulates adaptive changes in
B. burgdorferi during the transition between the tick vector and
mammalian host (91, 95). The RpoN–RpoS pathway relies on the
activity of RpoN (σ54), which controls the transcription of RpoS
(σS) through the binding to a canonical −24/−12 RpoN-type
promoter sequence (95, 193). The activation of the σ54-σS
cascade, in turn, is modulated by a bacterial enhancer-binding
protein (bEBP)/σ54-dependent activator (Rrp2) in concert with
BosR (91, 95, 193–198). After the activation, RpoS acts as a global
gene regulator controlling the expression of over 100 different
genes involved in stress responses, host infection and survival,
including biofilm formation (87, 95, 182).
Mutant strains of B. burgdorferi lacking RpoN, RpoS,
presented a less compact biofilm with loose and dispersed small
aggregates compared to wild-type strains (182). Notably,
all mutants expressed Borrelia biofilm markers such as
alginate, extracellular DNA, and calcium, although they showed
significantly higher sensitivity to low MIC dose of doxycyline
(0.1µg/ml) than the wild-type strain (182). In addition, the
quorum sensing (QS) molecules LuxS also contributes to
B. burgdorferi biofilm. The QS signaling system is a cell-to-cell
communication mechanism, shared by different bacteria, which
is based on the release of small molecules called autoinducers
(AI) in environment (199). LuxS pathways regulate biofilm
formation in various ways according to bacterial species and
environmental conditions (183). Specifically, luxS mutant
strains of Streptococcus gordonii and Porphyromonas gingivalis,
which are two important components of dental plaque, are
unable to produce a mixed-species biofilm (200). Besides, in
Helicobacter pylori the presence of luxS mutation leads to a
more efficient biofilm formation than the wild type whereas a
luxS mutant of Streptococcus mutans shows an altered biofilm
structure (183, 201–203). B. burgdorferi significantly increases
transcription of luxS during transition from ticks to mammalian
hosts where it is involved in the regulation of several genes
such as vlsE, erpA, and ipLA7 (204–207). luxS mutant strains in
stationary cultures of B. burgdorferi showed a higher tendency
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FIGURE 1 | (A) Confocal microscopy images of B. burgdorferi B31 strain (American Type Tissue Collection 35210) biofilms. Upper panel show the X-Y planes (top
view), while the lower panel show the Z section (side view). The sample was stained with BacLight Live/Dead (Invitrogen Life Technologies, Carlsbad, CA, USA) (188).
Representative images of biofilms developed on polystyrene pegs following 72 h incubation at 37◦C. Spirochetes were grown in a µ-Slide 8-well system (ibidi,
Germany) and cultured in BSK-H medium containing 6% rabbit serum (Sigma-Aldrich). (B) Schematic representation of a B. burgdorferi biofilm. The biofilm matrix
produced by spirochetes (green) provides shelter from host defenses, and reduces the diffusion of antibiotics. Persister forms of B. burgdorferi (in blue), exhibit
multidrug tolerance and are likely responsible for the recalcitrance of chronic LB. The illustration is adapted from Mind the Graph (https://mindthegraph.com) under the
Creative Commons License.
to form smaller and looser aggregates and a greater sensitivity to
antibiotics than the wild-type counterpart (182).
Although antibiotic treatment resolves most of clinical
manifestations of LB, persistent forms occur in ∼10% of
patients after treatment for erythema migrans disease (208,
209). The long-term persistence of symptoms and failure of
the antibiotic therapy are reminiscent of chronic biofilm-
associated infections. Biofilm aggregates display an enhanced
tolerance to various antibiotics, which, conversely, are effective
against the planktonic spirochetes and round body forms of
B. burgdorferi (210). In particular, doxycycline and amoxicillin
were found to effectively kill the motile spirochete forms
in vitro, but failed to completely remove B. burgdorferi in
biofilms (20, 21, 24, 26, 210–214). High throughput screens
of B. burgdorferi identified several promising Food and Drug
Administration (FDA)-approved drugs that have excellent anti-
persister activity (24, 181, 213, 215). Among them, daptomycin,
which is a lipopeptide targeting bacterial cell membranes,
clofazimine, carbomycin, sulfa drugs such as sulfamethoxazole,
and certain cephalosporins such as cefoperazone, showed higher
activity against B. burgdorferi persister cells resulting more
effective than doxycycline or amoxicillin (213). Although the
combination of these drugs was found to be active against
B. burgdorferi persisters, they showed poor activity when used
individually (24). Daptomycin was found to be the most active
antibiotic when combined with doxycycline plus either beta-
lactams like cefoperazone or carbenicillin or alternatively with
clofazimine (212). Daptomycin in combination with doxycycline
and cefoperazone was found to be able to completely eradicate
B. burgdorferi persisters, revealing a durable killing activity that
was not achieved by any other drug combinations (212). These
results where further supported by prospective randomized
clinical studies which failed to demonstrate significant beneficial
effect of additional prolonged therapy with doxycycline,
amoxicillin or ceftriaxone inmonotherapy, in patients with Lyme
encephalopathy and post-treatment symptoms of Lyme disease
(176, 215).
In addition to biofilm formation, the ability of Borrelia
to localize intracellularly in the host has been proposed as a
mechanismwhichmight favor chronic or persistent infection and
may contribute in reducing the efficacy of antibiotics. However,
Borrelia predominantly occupies the extracellular matrix, and the
antibiotics recommended for the treatment of LB are first-line
drugs in several intracellular infections (216, 217). Doxycycline
and azithromycin are commonly used for the treatment of
Mycoplasma, Chlamydia, and Legionella, while ceftriaxone is
effective against Salmonella and Neisseria, and amoxicillin is
used to treat Listeria infections (217, 218). Nevertheless, biofilm
production by extracellular bacteria and intracellular localization
of Borrelia are not mutually exclusive and may both participate
in supporting chronic bacterial persistence in the host.
On the other hand, a polymicrobial infection is a frequent
occurrence in ticks (219, 220). Chronic and persistent forms of
Lyme have been also associated to infections caused by Babesia
spp. and Anaplasma phagocytophilum, Bartonella henselae, or
other minor pathogens (217, 219, 221). This condition may
add a further level of complexity to the clinical and therapeutic
management of LB since it may lead to inappropriate diagnoses
and apparent failure of the antibiotic treatment targeted
exclusively against Borrelia. However, the real clinical relevance
of these coinfections is unclear and requires further, more in
depth evaluation.
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CONCLUDING REMARKS
LNB is the most dangerous manifestation of Lyme disease.
Although the early antimicrobial treatment is effective
in the majority of patients, persistent forms are relatively
common. The mechanisms underlying chronic LNB and other
persistent forms of Lyme are unknown. Patients who have
late manifestations of LB generally show a slower response to
therapy with incomplete resolution. Persistent Borrelia infection
requires prolonged antimicrobial treatment, with limited and
controversial clinical efficacy. Recent evidences suggest that the
antibiotic resistance and the reoccurrence of LB are associated
with biofilm-like aggregates, which allow Borrelia spp. to
resist to adverse environmental conditions. Several promising
FDA-approved drugs have been shown to have excellent anti-
persister activity when used in combination while their use
in monotherapy regimens showed a poor effectiveness. This
notion should be taken into careful consideration for the clinical
management of Lyme Disease in order to prevent long-term
complications.
In preliminary studies by the clinical Biofilm Ring Test R©
(cBRT), we found that Borrelia is able to readily produce biofilm
within 24–48 h. Diagnostic procedures such as the cBRT, which
allow for a rapid biofilm measurement may represent very
useful tools for clinical applications (222, 223), since the rapid
identification of biofilm-producing Borrelia strains, may help
identify forms of LB which are at risk of chronicity (224).
Further, characterization of Borrelia biofilm as well as the ensuing
inflammatory process will likely provide novel insight to better
understand the mechanism(s) concurring to LNB pathogenesis
and may offer new therapeutic targets for intervention.
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